Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 9, 2011, Pages 1395-1403

  Shea, Thomas ^a   Johnson, Jeffrey ^b   Westervelt, Peter ^c   Farag, Sherif ^d   McCarty, John ^e   Bashey, Asad ^f   Isola, Luis ^g   Baxter Lowe, Lee Anne ^h   Kelly, Michael ⁱ   Owzar, Kouros ^b   Linker, Charles ^h  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

Author keywords

Allo transplantation; Chemotherapeutic approches; Nonmyeloablative

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE PHOSPHATE; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; SIBLING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE PHOSPHATE;

EID: 80051663597     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.01.016     Document Type: Article

References (51)

1. Swenson W.T., Wooldridge J.E., Lynch C.F., et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005, 23:5019-5026.
2. Fisher R.I., LeBlanc M., Press O.W., et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23:8447-8452.
3. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
4. Tam S.T., Bassett R., Ledesma C., et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
5. Damon L.E., Johnson J.L., Niedzwiecki D., et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009, 27:6101-6108.
6. Geisler C.H., Kolstad A., Laurell A., et al. Front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2009, 112:2687-2692.
7. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
8. Hochster H., Weller E., Gascoyne R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009, 27:1607-1614.
9. Hallek M., Fingerle-Rowson G., Fink A.-M., et al. First-line treatment with fludarabine, cyclophosphamide, and rituximab improves overall survival in previously untreated patients with advanced chronic lymphocytic leukemia: results of a randomized Phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 2009, 114. [Abstract 535, p. 223].
10. van Oers M.H.J., Klasa R., Marcus R.E., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-3301.
11. Kaminski M.S., Tuck M., Estes M.A.J., et al. I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441-449.
12. Press O.W., Unger J.M., Braziel R.M., et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006, 24:4143-4149.
13. Morschhauser F., Radford J., Van Hoof A., et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26:5156-5164.
14. Buske C., Hoster E., Dreyling M., et al. Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group after a follow up of 58 months. Blood 2008, 112. [Abstract 2599, p.901].
15. Freedman A.S., Neuberg D., Mauch P., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999, 94:3325-3333.
16. Rohatiner A.Z., Nadler L., Davies A.J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007, 25:2554-2559.
17. Montoto S., Canals C., Rohatiner A.Z., et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007, 21:2324-2331.
18. Brown Jennifer R., Heather Yeckes, Jonathan W., et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin lymphoma. J Clin Oncol 2005, 23:2208-2214.
19. Bhatia S., Robison L.L., Francisco L., et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005, 105:4215-4222.
20. Gyan E., Foussard C., Bertrand P., et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009, 113:995-1001.
21. Micallef I.N., Lillington D.M., Apostolidis J., et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000, 18:947-955.
22. Lenz G., Dreyling M., Schiegnitz E., et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004, 22:4926-4933.
23. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003, 21:3918-3927.
24. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:2667-2674.
25. Sebban C., Brice P., Delarue R., et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008, 26:3614-3620.
26. Hiddemann W., Buske C., Kneba M., et al. Autologous stem cell transplanation after myeloablative therapy in first remission may be beneficial in patients with advanced stage follicular lymphoma after front-line therapy with R-CHOP. An analysis of 2 consecutive studies of the German Low Grade Lymphoma Study Group. Blood 2008, 112. [Abstract 772, p.286].
27. Ladetto M., De Marco F., Benedetti F., et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008, 111:4004-4013.
28. van Besien K., Loberiza F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521-3529.
29. Verdonck L.F., Dekker A.W., Lokhorst H.M., et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997, 90:4201-4205.
30. Arcaini L., Montanari F., Alessandrino E.P., et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008, 19:1331-1335.
31. Tarella C., Zanni M., Magni M., et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol 2008, 26:3166-3175.
32. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865-3871.
33. Laport G., Bredeson C.N., Tomblyn M., et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-Hodgkin lymphoma beyond first complete response or first partial response. J Clin Oncol 2008, 26. [Abstract 7041, p.382s].
34. Tomblyn M., Brunstein C., Burns L.J., et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:538-545.
35. Robinson S., Canals C., Blaise D., et al. Reduced-intensity allogeneic stem cell transplantation for follicular lymphoma results in an improved progression free survival when compared to autologous stem cell transplantation. An analysis from the Lymphoma Working Party of the EBMT. Blood 2008, 112. [Abstract 458, p.175].
36. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after non-myeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
37. Thomson K.J., Morris E.C., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:426-432.
38. Ingram W., Devereux S., Das-Gupta E.P., et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008, 141:235-243.
39. Pérez-Simón J.A., Kottaridis P.D., Martino R., et al. Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002, 100:3121-3127.
40. Shea T.C., Johnston J., Walsh W., et al. Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients with advanced indolent NHL and CLL: CALGB 109901. Blood 2007, 110. [Abstract 486].
41. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
42. Cheson B.D., Bennett J.M., Grever M.R., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
43. Sharf S.J., Smith A.G., Hansen J.A., et al. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995, 85:1954-1963.
44. Thomson K.J., Morris E.C., Milligan D., et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010, 28:3695-3700.
45. Vigouroux S., Michallet M., Porcher R., et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: A survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy. Haematologica 2007, 92:627-634.
46. Avivi I., Montoto S., Canals C., et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009, 147:719-728.
47. Rezvani A.R., Storer B., Maris M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:211-217.
48. Hari P., Carreras J., Zhang M.J., et al. Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008, 14:236-245.
49. Cohen S., Busque L., Kiss T., et al. Tandem autologous-allogeneic nonmyeloablative sibling transplant in relapsed follicular lymphoma leads to impressive progression free survival with minimal toxicity. Blood 2009, 114. [Abstract 50, p.26].
50. Mandigers C.M., Verdonck L.F., Meijerink J.P., et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003, 32:1159-1163.
51. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.